2.9 0 (0%) | 02-12 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 4.02 | 1-year : | 4.48 |
Resists | First : | 3.44 | Second : | 3.83 |
Pivot price | 3 ![]() |
|||
Supports | First : | 2.79 | Second : | 2.32 |
MAs | MA(5) : | 3 ![]() |
MA(20) : | 2.99 ![]() |
MA(100) : | 3.71 ![]() |
MA(250) : | 3.65 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 30 ![]() |
D(3) : | 45.4 ![]() |
RSI | RSI(14): 38.9 | |||
52-week | High : | 5.01 | Low : | 2.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MREO ] has closed above bottom band by 25.0%. Bollinger Bands are 44.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.94 - 2.96 | 2.96 - 2.98 |
Low: | 2.76 - 2.78 | 2.78 - 2.8 |
Close: | 2.87 - 2.9 | 2.9 - 2.93 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Tue, 11 Feb 2025
Mereo BioPharma: Good Science, Fairly Valued (NASDAQ:MREO) - Seeking Alpha
Sat, 25 Jan 2025
Brokerages Set Mereo BioPharma Group plc (NASDAQ:MREO) Target Price at $7.83 - MarketBeat
Mon, 13 Jan 2025
Mereo Biopharma Advances with Key Clinical Updates - TipRanks
Sun, 12 Jan 2025
Mereo BioPharma Provides Update on Lead Clinical Programs - GlobeNewswire
Tue, 07 Jan 2025
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Mon, 30 Dec 2024
Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 155 (M) |
Held by Insiders | 4.8993e+008 (%) |
Held by Institutions | 1 (%) |
Shares Short | 7,050 (K) |
Shares Short P.Month | 0 (K) |
EPS | -3.748e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 806.5 % |
Return on Equity (ttm) | -30.7 % |
Qtrly Rev. Growth | 1e+006 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -49.97 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -30 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.06 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 7.2e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |